Sigilon Therapeutics Inc (SGTX) Stock
SGTX is no longer traded. Sigilon Therapeutics Inc was delisted from the Nasdaq in August 2023.
Prices on this page are historical; the last trade was August 10, 2023 at $22.47.
Sigilon Therapeutics Inc stock price history
SGTX final trading statistics
- Final close
- $22.47
- Final trading day
- Aug 10, 2023
- Market cap at delisting
- $56.22M
- Shares outstanding
- 2.50M
- Final 52-week range
- $0.29 – $28.00
- Avg. volume (final 3 mo.)
- 129,129
- All-time high (split-adj.)
- $624.39 · Dec 2020
- All-time low (split-adj.)
- $3.80 · Dec 2022
- Return since IPO
- -95.0%
- Beta
- 4.12
- Book value / share
- $10.97
- Price / book
- 2.05
Sigilon Therapeutics Inc annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $12.94M | -$43.5M | -$1.35 |
| FY2021 | $9.60M | -$78.2M | -$2.43 |
| FY2020 | $13.37M | -$54.9M | -$4.79 |
| FY2019 | $14.15M | -$44.6M | -$10.70 |
| FY2018 | $4.64M | -$22.8M | -$2.53 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Sigilon Therapeutics Inc
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sigilon Therapeutics Inc stock FAQ
What happened to Sigilon Therapeutics Inc stock?
Sigilon Therapeutics Inc stock was delisted from the Nasdaq. Its final close was $22.47 on August 10, 2023.
Is SGTX stock still trading?
No. SGTX was delisted from the Nasdaq in August 2023 and no longer trades on a U.S. exchange.
What was the last price of SGTX stock?
SGTX closed at $22.47 on its final trading day, August 10, 2023, for a market value of about $56.22M.
What were Sigilon Therapeutics Inc's revenue and earnings in its last full fiscal year?
Sigilon Therapeutics Inc reported revenue of $12.94M and net income of -$43.5M in fiscal 2022, its last full year as a public company.
When did Sigilon Therapeutics Inc go public?
Sigilon Therapeutics Inc stock began trading on December 4, 2020.